Simvastatin reduces NF-κB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet

Cardiovascular Research

Volumn 57, Issue 1, 2003, Pages 168-177

  Hernández Presa, Miguel Angel ^a   Ortego, M ónica ^a   Tuñón, José ^a   Martín Ventura, José Luis ^a   Mas, Sebastián ^b   Blanco Colio, Luis Miguel ^a   Aparicio, César ^c   Ortega, Luis ^d   Gómez Gerique, Juan ^c   Vivanco, Fernando ^b   Egido, Jesús ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Atherosclerosis; Cholesterol; Gene expression; Infection inflammation; Macrophages; Statins

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LIPID; SIMVASTATIN; STROMELYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENIC DIET; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL INFILTRATION; CONTROLLED STUDY; DIET THERAPY; DRUG BINDING; DRUG EFFECT; GEL MOBILITY SHIFT ASSAY; HISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPID BLOOD LEVEL; MACROPHAGE; MALE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SOUTHWESTERN BLOTTING;

ANIMALS; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; DIET, ATHEROGENIC; FEMORAL ARTERY; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MACROPHAGE ACTIVATION; MALE; MATRIX METALLOPROTEINASE 3; MODELS, ANIMAL; NF-KAPPA B; RABBITS; RANDOM ALLOCATION; SIMVASTATIN;

EID: 12244297142     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00619-3     Document Type: Article

References (47)

1. Ross R. Atherosclerosis: an inflammatory disease. New Engl J Med. 340:1999;115-126.
2. Falk E., Shah P.K., Fuster V. Pathogenesis of plaque disruption. Fuster V., Ross R Topol E.J. Atherosclerosis and coronary artery disease. 1996;491-507 Lippincott-Raven, Philadelphia, PA.
3. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
4. Davies M.J. Stability and instability: two faces of coronary atherosclerosis. Circulation. 94:1996;2013-2020.
5. Van der Wal A.C., Becker A.E., Van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
6. Moreno P.R., Falk E., Palacios I.F., et al. Macrophage infiltration in acute coronary syndromes: implication for plaque rupture. Circulation. 90:1994;775-778.
7. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix-metalloproteinases and matrix-degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 94:1994;2493-2503.
8. Aikawa M., Rabkin E., Okada Y., et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma. Circulation. 97:1998;2433-2444.
9. Bustos C., Hernández-Presa M.A., Ortego M., et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 32:1998;2057-2064.
10. Hernández-Presa M.A., Martín-Ventura J.L., Ortego M., et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis. 160:2002;49-58.
11. Sparrow C.P., Burton C.A., Hernandez M., et al. Simvastatin has antiinflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 21:2001;115-121.
12. Soma M.R., Donetti E., Parolini C., et al. HMG-CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb. 13:1993;571-578.
13. Soma M.R., Parolini C., Donetti E., Fumagalli R., Paoletti R. Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cells proliferation. J Cardiovasc Pharmacol. 25:1995;S20-S24.
14. Laufs U., LaFata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
15. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 101:1998;2711-2719.
16. Corsini A., Raiteri M., Soma M.R., et al. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol. 76:1995;21A-28A.
17. Giroux L.M., Davignon J., Naruszewic M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochem Biophys Acta. 1165:1993;335-338.
18. Colli S., Eligini S., Lalli M., et al. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol. 17:1997;265-272.
19. Barnes P.J., Karin M. Nuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseases. New Engl J Med. 336:1997;1066-1071.
20. Bond M., Baker A.H., Newby A.C. Nuclear factor kappaB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun. 264:1999;561-567.
21. Collins T. Endothelial nuclear factor κB and the initiation of the atherosclerotic lesion. Lab Invest. 68:1993;499-508.
22. Egido J., Hernández-Presa M.A., Tuñón J., et al. Transcription factor κB (NF-κB) and cardiovascular disease. Cardiovascular Risk Factors. 9:1999;159-168. ( www.crf.medynet.com ).
23. Brand K., Page S., Bartsch A., et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 97:1996;1715-1722.
24. Hernández-Presa M.A., Bustos C., Ortego M., et al. The ACE inhibitor quinapril reduces the arterial expression of NF-κB dependent proinflammatory factors but not of collagen in a rabbit model of atherosclerosis. Am J Pathol. 153:1998;1825-1837.
25. Wilson S.H., Best P.J., Edwards W.D., et al. Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis. 160:2002;147-153.
26. Hernández-Presa M., Bustos C., Ortego M., et al. Angiotensin converting enzyme inhibition prevents arterial NF-κB activation, MCP-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 95:1997;1532-1541.
27. Tsukada T., Rosenfeld M.E., Ross R., Gown A.M. Immunocytochemical analysis of cellular components in atherosclerotic lesions: use of monoclonal antibodies with the Watanabe and fat-fed rabbit. Atherosclerosis. 6:1986;601-613.
28. Hernández-Presa M.A., Gómez-Guerrero C., Egido J. In situ non-radioactive detection of nuclear factors in paraffin sections by Southwestern histochemistry. Kidney Int. 55:1999;209-214.
29. Blanco-Colio L.M., Valderrama M., Alvarez-Sala L.A., et al. Red wine intake prevents nuclear factor-κB activation in peripheral blood mononuclear cells of healthy volunteers during postprandial lipemia. Circulation. 102:2000;1020-1026.
30. Brown B.G., Fuster V. Impact of management in stabilization of coronary disease. Fuster V., Ross R., Topol E.J. Atherosclerosis and coronary artery disease. 1996;191-205 Lippincott-Raven, Philadelphia, PA.
31. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
32. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med. 333:1995;1301-1307.
33. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
34. Dangas G., Badimon J.J., Smith D.A., et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol. 33:1999;1294-1304.
35. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1991;425-430.
36. Gibbs J.B., Oliff A., Kohl N.E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell. 77:1994;175-178.
37. Finco T.S., Baldwin A.S. κB site-dependent induction of gene expression by diverse inducers of nuclear factor kB requires Raf-1. J Biol Chem. 268:1993;17676-17679.
38. Ortego M., Bustos B., Hernández-Presa M.A., et al. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 147:1999;253-261.
39. Nikkari S.T., O'Brien K.D., Ferguson M., et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation. 92:1995;1393-1398.
40. Brown D.L., Hibbs M.S., Kearney M., Loushin C., Isner J.M. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Circulation. 91:1995;2125-2131.
41. Li Z., Li L., Zielke R., et al. Increased expression of 72-kd Type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol. 148:1996;121-128.
42. Gerszten R.E., Garcia-Zepeda E.A., Lim Y.C., et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 3998:1999;718-723.
43. Mach F., Sauty A., Iarossi A.S., et al. Differential expression of three lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest. 104:1999;1041-1050.
44. Romano M., Diomede L., Sironi M., et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest. 80:2000;1095-1100.
45. Williams J.K., Sukhova G.K., Herrington D.M., Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 31:1998;684-691.
46. Pruefer D., Scalia R., Lefer A.M. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol. 19:1999;2894-2900.
47. Scalia R., Gooszen M.E., Jones S.P., et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation. 103:2001;2598-2603.